ArticleDiabetes, obesity & metabolism2025
Long-term use of Minimed™ 780G in children and adolescents with type 1 diabetes under real-world conditions: The benefits of optimal settings.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes.Diabetes, obesity & metabolism · 2026Pooled it
- Device Usage Characteristics and Glycaemic Control in Indian Adolescents with Type-1 Diabetes Using the MiniMed™ 780G System.Indian journal of pediatrics · 2026Article
- Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Effects of switching from MiniMed™ 770G to 780G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.Journal of diabetes investigation · 2026Observational
- Challenges in glycaemic control among women with type 1 diabetes and the role of MiniMed 780G system: A narrative review.Diabetes, obesity & metabolism · 2026Review
- Long-term use of Minimed™ 780G in children and adolescents with type 1 diabetes under real-world conditions: The benefits of optimal settings.Diabetes, obesity & metabolism · 2025Article
- Real-world efficacy of MiniMed™780G recommended settings (glycemic target 100 mg/dL, active insulin time 2 hours) in youth and young adults with type 1 diabetes.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.